The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
These abstracts report on the company's three lead drug candidates, including olverembatinib
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Further strengthens BaseLaunch's global pharma industry partnerships
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Establishing Asymchem’s first manufacturing footprint in Europe
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Subscribe To Our Newsletter & Stay Updated
